BACE1 is the putatively rate-limiting initiating enzyme in Aβ generation, and it is considered a prime drug target for lowering cerebral Aβ levels in the treatment and/or prevention of AD [24]. This evidence concerns the gene BACE1 and Alzheimer disease.